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Hepatitis B virus (HBV)-reverse seroconversion (RS) following allogeneic hematopoietic stem cell transplan-
tation (allo-HSCT) is a frequent late-onset complication in recipients with previous HBV infection. We fol-
lowed 38 allo-HSCT recipients with previous HBV infection, and conducted posttransplant HB vaccine
intervention in 13 recipients. First, we followed the recipients without any intervention (historic control)
until 2003; hence, we commenced HB vaccination. Out of the patients who underwent transplantation after
2003, 13 recipients were immunized by a standard three-dose regimen after immunosuppressant cessation
(vaccine group), whereas 12 recipients were observed without any intervention (nonvaccine group). Eight of
the 13 historic control group recipients and 3 of the 12 nonvaccine group recipients, but none of the 13 vac-
cine group recipients, suffered HBV-RS. Cumulative risks of HBV-RS at 3 years post-HSCT in the historic
control, nonvaccine and vaccine groups were 41%, 39%, and 0% respectively (P 5 .022). We therefore con-
clude that intervention with HB vaccines is significantly effective in preventing post-HSCT HBV-RS.
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nant hepatitis B vaccineINTRODUCTION
Hematopoietic stem cell transplantation (HSCT)
is performed worldwide to treat various diseases,
including hematologic malignancies. Intensive che-
motherapy and immunosuppression in patients who
undergo HSCT result in immune dysfunction, putting
these patients at high risk for infection, not only with
external pathogens but also internal ones. Reactivation
of herpes viruses such as herpes simplex (HSV), vari-
cella zoster (VZV), human herpes virus 6 (HHV6), Ep-
stein-Barr (EBV), and cytomegalovirus (CMV), for
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doi:10.1016/j.bbmt.2008.08.007instance, are well-known phenomena in such patients;
recently hepatitis B virus (HBV) has also been recog-
nized to be reactivated following HSCT [1-4].
The appearance of antihepatitis B surface antigen
antibody (anti-HBs) and the clearance of HBV from
the serum usually indicate resolution of hepatitis in
patients infected with HBV. However, most patients
in whomHBV has been eliminated from the serum still
have HBV DNA in the liver that is detectable by poly-
merase chain reaction (PCR) [5]. Reactivation of dor-
mant HBV in the liver has been observed in an
immunocompromised status, such as HSCT, renal
transplantation, intensive chemotherapy, or rituximab
use [6-13]. The reactivation of hepatitis in anti-HBs-
positive patients is known as reverse seroconversion
(RS).Previously,wehave revealed thatRS is a late-onset
complication with high frequency that can be predicted
by careful monitoring of the progressive disappearance
of anti-HBs [1]. From earlier observations, we consider
that RS hepatitis afterHSCT is a hepatitis caused by re-
constituted naı¨ve donor immunity, following the loss of
recipient-derived immunity against HBV.
In the current study, we conducted posttransplant
recombinant HB (rHB) vaccine intervention to
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clinical efficacy in preventing posttransplant HBV-RS.
PATIENTS AND METHODS
Patients Studied
Allo-HSCT recipients who underwent transplan-
tation in our hospital, from February 1990 to March
2007, and who were followed for at least 1 year after
HSCT, were enrolled in this study.We retrospectively
studied 38 recipients with previous HBV infection in
the pre-HSCT evaluation. We started hepatitis B vac-
cine intervention inHSCT recipients after cessation of
immunosuppressant administration, in March 2003.
One cycle consisted of a 3-dose schedule, given at 0,
1, and 6 months. Yeast-derived rHB vaccines contain-
ing the major surface protein (Bimmugen, Astellas
Pharmaceutical, Tokyo; Heptavax-II, Merck & Co.,
Whitehouse Station) were used. Thirteen recipients,
who underwent transplantation after March 2003,
were immunized with HB vaccine using a standard
regimen (vaccine group). Twelve recipients, who also
underwent transplantation after March 2003, were ob-
served without intervention, either because of follow-
up in their regional hospital (5 cases), because of the
physician’s decision (4 cases), or because of prolonged
administration of immunosuppressant (3 cases) (non-
vaccine group). Data regarding the progress of the pa-
tients who were followed up in their regional referral
hospital were obtained through the respective hema-
tologist in charge. Thirteen recipients who underwent
transplantation beforeMarch 2003, and were observed
without vaccine intervention, were considered as con-
trols (historic control group). We studied the transi-
tion of anti-HBs and the incidence of HBV-RS.
Patients’ characteristics are shown in Table 1. Reflect-
ing the historic background, the number of reduced in-
tensity stem cell transplantation (RIST) and median
age were higher in vaccine and nonvaccine groups
compared to the historic control group. All variables
are equivocal between the vaccine and nonvaccine
groups. This study was approved by the institutional
review board of the Hokkaido University School of
Medicine.
Definitions
Previous HBV infection was diagnosed serologi-
cally. Recipients with (HBsAg [2], anti-HBs [1],
anti-HBc [1]) and (HBsAg [2], anti-HBs [2],
anti-HBc [1]) were both considered to have had
previous HBV infection. In patients with (HBsAg
[2], anti-HBs [1], anti-HBc [2]), we diagnosed
with previous HBV infection only after confirming
that they had never received rHB vaccination, because
normally rHB vaccination responders show the sameserologic patterns. RSwas defined as the disappearance
of anti-HBs and the appearance of HBsAg and HBV-
DNA in the serum, regardless of the presence of clinical
hepatitis. Vaccine responders were defined with anti-
HBs levels .10 mIU/mL, which are considered to be
protective. In patients whose anti-HBs titerwas already
.10 mIU/mL at the prevaccination point, vaccine re-
sponders were determined by their tendency to in-
crease anti-HBs levels after vaccination.
Statistics
The primary endpoint was the occurrence of RS.
The risks of the endpoints were estimated using the
Kaplan-Meier method. The Kaplan-Meier curves were
compared using the log-rank test.
RESULTS AND DISCUSSION
Progressive decreases in anti-HBs titers were
observed in all pre-HSCT anti-HBs-positive recipi-
ents. In the vaccine group, the first vaccine started at
6-29 months (median 17 months) after HSCT. In 8
of the 13 pre-HSCT-anti-HBs-positive recipients,
the anti-HBs titer had already decreased to undetect-
able levels at the time of the first vaccine. Four of the
13 recipients (31%) responded to initial courses of
the HB vaccine. Three of the 4 vaccine responders
responded after the third vaccine (Figure 1A). Eight
of the 13 historic control group recipients and 3 of
the 12 nonvaccine group recipients suffered HBV-RS
following loss of anti-HBs, but none of the 13 vaccine
group recipients suffered HBV-RS. Characteristics of
the 11 recipients with RS are shown in Table 2. Only 2
of the 8 historic control group recipients (cases 1 and 5
in Table 2), and none of the 3 nonvaccine group recip-
ients, suffered HBV-RS during immunosuppressant
administration. All recipients with RS lost anti-HBs
prior to the occurrence of RS. Cumulative risks of
HBV-RS at 3 years post-HSCT in the historic control,
nonvaccine group, and vaccine group were 41%, 39%,
and 0%, respectively (P 5 .022) (Figure 1B).
Table 1. Patients’ Characteristics
Historic control
(1990-2002)
Non vaccine
group (2003-)
Vaccine group
(2003-)
Case number 13 12 13
Male/ female 9/4 5/7 6/7
Age (median) 22-52 (36) 25-65 (47) 24-68 (50)
Follow-up(median) (month) 17-116 (59) 12-55 (23) 20-60 (37)
CST/RIST 13/0 5/7 10/3
CsA+sMTX/FK+sMTX 11/2 8/4 9/4
Acute GVHD
Grade 0-1 11 7 6
Grade II-IV 2 5 7
Chronic GVHD (no/yes) 2/11 4/8 4/9
CST indicates conventional stem cell transplantaion; RIST, reduced-in-
tensity stem cell transplantation; sMTX, short-term methotrexate;
CsA, cyclosporin A; FK, tacrolimus; GVHD, graft-versus-host disease.
1228 Biol Blood Marrow Transplant 14:1226-1230, 2008M. Onozawa et al.Figure 1. (A) Immunization effect of HB vaccination. Transition of anti-HBs in the ‘‘vaccine group’’ from the pre-HSCT to the prevaccination point, and
from the prevaccination point onward, is plotted. Although 8 of the 13 recipients (fine line) showed an increase in anti-HBs, only 4 recipients (bold line)
showed an increase in anti-HBs levels.10 mIU/mL. Non-responders are depicted with dotted lines in the graph. (B) Cumulative incidence of posttrans-
plant HBV-RS. There were no differences between the ‘‘historic control group’’ and the ‘‘nonvaccine group’’ (P5 .74). The ‘‘vaccine group’’ showed a sig-
nificantly lower risk for HBV-RS than the other 2 groups (P 5 .022).Although patients with HBsAg have clearly been
shown to be a high-risk group for liver complications,
little attention has been paid to patients having anti-
HBs when performing HSCT [2]. In Japan, the popu-
lation of patients having had previous HBV infection
(15%–20%) is more than 10 times higher than that
of HBsAg-positive carriers (1%). Our previous obser-
vations revealed that sustained anti-HBs is crucial to
prevent dormant HBV to reactivate, because all
HBV-RS occurred following the loss of anti-HBs [1].
In patients with resolved HBV infection, the
progressive disappearance of anti-HBs is inevitable;
occurring with the progressive loss of recipient-type
immune cells, regardless of the pretransplantation
anti-HBs titer [1,3,4]. Thus, patients with resolved
HBV infection should be considered to be a high-
risk group for HBV reactivation because of the persis-
tence of the virus in a ‘‘latent’’ state in the liver. HBV
reactivation from dormant HBV, which remains in
the liver after the initial infection, was first recognized
in the liver transplantation field [14]. Uemoto et al.
[15] reported that of 16 recipients with no prior history
ofHBV infection, who underwent liver transplantation
from anti-HBc-positive and HBsAg-negative living
donors, 15 (93.75%) became HBsAg-positive after
transplantation. Apart from proving the existence of
HBV-DNA in liver tissues, even after serologic resolu-
tion of HBV infection, they also discovered that HBV
is transmitted to recipients by liver grafts from anti-
HBc-positive donors at a significantly high rate. In
the liver transplantation field, the use of a preventive
measure, which basically entails creating passive
immunity by means of hepatitis B immunoglobulin
(HBIG) and lamivudine, has already been established.
However, because of the limited commercial supply of
HBIG as well as the lifelong requirement for prophy-
laxis following transplantation, financial constraints
represent a debilitating problem to this therapy.Moreover, despite the use of rHB vaccination to
reduce the frequency of HBIG support, active immu-
nization showed limited effect under sustained usage
of immunosuppressants [16].
RS of HBV following HSCT, and HBV reactiva-
tion following liver transplantation from donors with
previous HBV infection are reciprocal phenomena.
The most important difference between solid organ
transplants and HSCT is the span of immunosuppres-
sant usage. In solid organ transplants immunosuppres-
sant administration is lifelong, but inHSCT, immunity
is reconstituted and treatment with immunosuppr-
essants can be stopped. We therefore hypothesized
that active immunization by rHB vaccinemight be use-
ful in avoiding HBV-RS after HSCT. The safety and
efficacy of rHB vaccination in HSCT recipients has al-
ready been reported [17]. Some guidelines for post-
transplant vaccination recommend rHB vaccination,
mainly to prevent de novo infection of HBV from
outside the body. It was the EuropeanGroup for Blood
and Marrow Transplantation (EBMT), which for
the first time proposed the use of rHB vaccination to
prevent innate HBV reactivation as a posttransplant
vaccination option [18]. The clinical efficacy of the
rHB vaccine in preventing posttransplant HBV-RS,
however, has not been previously reported. Notwith-
standing that this study is a nonrandomized historic
case-control study, this is the first report in which the
usefulness of HB vaccine in preventing HBV-RS after
HSCT has been investigated.
Several studies have recommended prophylactic
vaccination of the donor, expecting adoptive transfer
of HBV immunity; a well-described phenomenon in
the literature [9-11,19], regrettably however, attempts
to overcome immunodeficiency by immunizing the
donor have not always been successful [4,20]. Long-
term immunity, defined as the persistence of antibody
presence, is not achieved without reexposure to the
Pre-HSCT-
anti-HBc
Pre-HSCT-
anti-HBs
(mIU/mL)
Loss of
anti-HBs
(<10 miU/mL)
(Month after
HSCT)
Cessation of
Immuno-
suppressant
(Month after
HSCT)
RS Onset
(Month
after
HSCT)
HBV-DNA
PCR (Log
Copy/mL)
Max
AST
(U/L)
Duration
of
Hepatitis
(Month)
HBV
Genotype Outcome
(+) 37.2 13 20 17 4.7 1059 2 C Re-seroconversion
(+) 445 33 20 51 5.6 1460 2 BJ Re-seroconversion
(+) 1650 21 5 21 >7.6 196 3 C Healthy carrier
(+) 10000 16 15 17 4.4 207 2 C Re-seroconversion
(+) 152 12 13 12 3.5 264 2 C Re-seroconversion
(+) 167 38 5 38 2.8 197 3 C Re-seroconversion
(+) 32.9 12 14 20 >7.6 212 3 C Healthy carrier
(+) 6510 24 8 50 N/A WNL no hepatitis N/A Healthy carrier
(+) 2.5 0 4 24 7.3 1197 2 BJ Re-seroconversion
(+) negative 0 3 17 8.9 50 3 C Healthy carrier
(+) negative 0 9 14 NA 1238 2 NA Re-seroconversion
odysplastic syndrome; MM, multiple myeloma; BMT, bone marrow transplantation; CBT, cord blood transplantation; CST,
TX, short-term methotrexate; CsA, cyclosporin A; FK, tacrolimus; GVHD, graft-versus-host disease; AST, aspartate
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TTable 2. Characteristics of 11 recipients with HBV-RS
No. Group Age Sex Disease Type of HSCT
Conditioning
Regimen
Prophylaxis
of GVHD
Acute
GVHD
Chronic
GVHD
1 Histrical
control
36 M CML related BMT CST CsA+sMTX 0 (+)
2 Histrical
control
35 F CML unrelated BMT CST CsA+sMTX II (+)
3 Histrical
control
47 F ALL unrelated BMT CST CsA+sMTX I (+)
4 Histrical
control
25 F MDS related BMT CST CsA+sMTX I (+)
5 Histrical
control
26 M ALL related BMT CST CsA+sMTX I (+)
6 Histrical
control
40 M MDS related BMT CST CsA+sMTX 0 (+)
7 Histrical
control
52 M CML unrelated BMT CST CsA+sMTX II (+)
8 Histrical
control
38 F CML unrelated BMT CST FK+sMTX III (+)
9 Nonvaccine 65 M MM CBT RIST CsA+sMTX II (+)
10 Nonvaccine 48 M MDS related BMT RIST CsA+sMTX 0 (2)
11 Nonvaccine 38 F CML unrelated BMT CST FK+sMTX III (2)
CML indicates chronic myelogeneous leukemia; ALL, acute lymphoblastic leukemia; MDS, myel
conventional stem cell transplantation; RIST, reduced-intensity stem cell transplantation; sM
aminotransferase; WNL, within normal limit; NA, not analyzed.
Cases 1–7 in Table 2 were reported in our previous paper [1].
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tion, regardless of the immune status of the donor
[3,20]. In our study, the rate of successful vaccinations
was lower than that described in a previous report [17].
Interestingly, however, in our study, 4 of the 9 nonre-
sponders (44%) showed a slight increase in their anti-
HBs titer after HB vaccination, even though the
responder criteria (.10 mIU/mL) were not met. We
still do not know the exact minimal titer of anti-HBs,
necessary to prevent HBV-RS completely. Conse-
quently, in nonresponders, an intensified dose or
schedule, possibly using another rHB vaccine, should
be taken into consideration.
In conclusion, RS is a late-onset complication with
high frequency following HSCT, which can be pre-
dicted by careful monitoring of the progressive disap-
pearance of anti-HBs. In view of the results obtained in
this study we propose rHB vaccination of recipients as
a valuable prophylactic tool for the reactivation of
HBV in allo-HSCT patients.
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